37,900€
2,43%
Echtzeit-Aktienkurs Surmodics Inc.
Bid:
Ask:
Echtzeit-Chart der Surmodics Inc. Aktie
Börsenkurse Surmodics Inc.
| Echtzeit Euro | - | - | - | - | 37,900€ | 0,80% |
| Echtzeit USD | - | - | - | - | 39,671$ | 0,46% |
| Lang & Schwarz | - | - | - | - | 37,900€ | 0,53% |
| Börse Frankfurt | - | - | - | - | 37,900€ | 2,99% |
| Tradegate | - | - | - | - | 37,900€ | 0,80% |
| gettex | - | - | - | - | 37,900€ | 0,53% |
| USA | - | - | - | - | 39,490$ | -0,30% |
| Börse Stuttgart | - | - | - | - | 37,900€ | 2,43% |
| Nasdaq | - | - | - | - | 39,880$ | 0,99% |
Fundamentaldaten der Surmodics Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 132,58 Mio. | 2,49 Mio. | -1,54 Mio. | -0,11 | - | - | 4,05 |
| 2022 [USD] | 99,95 Mio. | -22,49 Mio. | -27,27 Mio. | -1,96 | - | - | 5,32 |
| 2021 [USD] | 105,14 Mio. | 6,35 Mio. | 4,24 Mio. | 0,30 | - | 125,08 | 5,01 |
| 2020 [USD] | 94,86 Mio. | -1,45 Mio. | 1,12 Mio. | 0,08 | - | 467,90 | 5,46 |
| 2019 [USD] | 100,08 Mio. | 7,56 Mio. | 7,59 Mio. | 0,55 | - | 68,78 | 5,11 |
| 2018 [USD] | 81,34 Mio. | -7,53 Mio. | -4,46 Mio. | -0,34 | - | - | 6,24 |
| 2017 [USD] | 73,11 Mio. | 7,03 Mio. | 3,93 Mio. | 0,29 | - | 130,69 | 6,79 |
| 2016 [USD] | 71,37 Mio. | 16,95 Mio. | 9,99 Mio. | 0,76 | - | 49,87 | 7,01 |
| 2015 [USD] | 61,90 Mio. | 18,24 Mio. | 11,95 Mio. | 0,90 | - | 42,16 | 7,93 |
| 2014 [USD] | 57,44 Mio. | 18,47 Mio. | 12,03 Mio. | 0,87 | - | 43,56 | 8,98 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Surmodics Inc. Aktie
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.